Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR vs ANOQUAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
Hypertension
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
100 mg orally twice daily
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Hepatic metabolism via oxidation and conjugation; metabolites excreted renally.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
99% bound; primary binding protein: albumin.
Approximately 90% bound to albumin.
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
0.8-1.2 L/kg, indicating extensive distribution into total body water.
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Oral: 60-70% due to first-pass metabolism.
No dosage adjustment required for renal impairment.
GFR 30-50 m L/min: 100 mg once daily; GFR <30 m L/min: 50 mg once daily; not recommended for GFR <15 m L/min
No dosage adjustment required for hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended
Safety and efficacy in pediatric patients have not been established; use not recommended.
Not approved for pediatric use; no established dosing
No specific dosage adjustment required; use same dosing as for younger adults.
No specific adjustment; monitor renal function and consider reduced initial dose (50 mg twice daily) in patients >65 years with renal impairment
No FDA boxed warning.
No FDA black box warning.
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Rebound hypertension upon abrupt discontinuation; sedation and drowsiness; potential for orthostatic hypotension; caution in patients with severe coronary insufficiency or cerebrovascular disease.
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Known hypersensitivity to guanabenz; patients with severe hepatic or renal impairment.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
Avoid grapefruit and grapefruit juice as they may increase quinine levels. Take with a full glass of water. May be taken with meals to reduce nausea.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and third trimester exposure is associated with fetal nephrotoxicity, oligohydramnios, and premature closure of the ductus arteriosus.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Excreted in human milk. M/P ratio not determined. Avoid breastfeeding due to potential for serious adverse reactions in the nursing infant, including renal impairment and electrolyte disturbances.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
Anoquan is contraindicated in pregnancy; no dose adjustments are recommended because use during pregnancy is not advised.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
ANOQUAN (quinine sulfate) is used for uncomplicated Plasmodium falciparum malaria. Monitor for cinchonism (tinnitus, headache, nausea). Avoid in G6PD deficiency due to hemolysis risk. Correct hypoglycemia frequently. Use with caution in atrial fibrillation due to QT prolongation.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
Take with food to reduce gastrointestinal upset.,Complete full course even if symptoms improve.,Report ringing in ears, confusion, or vision changes.,Avoid driving if dizziness or visual disturbances occur.,Inform doctor of any history of G6PD deficiency or cardiac arrhythmias.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR vs ANOQUAN, answered by our medical review team.
ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. ANOQUAN is a Local Anesthetic that works by Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR and ANOQUAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. The standard adult dose of ANOQUAN is: 100 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR and ANOQUAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. ANOQUAN is classified as Category C. Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.